How to Sell an Independent Pharmacy

Independent pharmacy is a business where the revenue line has been under sustained pressure and the surviving operators are the ones who built something beyond the retail counter. Buyers know this, so they underwrite the mix rather than the volume. An owner planning an exit needs to understand which parts of the business a buyer actually wants and which parts are being priced as a declining annuity.

Script count is the wrong headline number

Every pharmacy owner knows their daily script count, and it is the first number most volunteer. It is also the least informative. What a buyer wants is gross margin per script, and the distribution of scripts across payer types. Generic scripts at reasonable acquisition cost carry margin; brand scripts often carry almost none and can be dispensed below cost after fees. Medicare Part D volume behaves differently from commercial. Cash-pay, compounded, and durable medical equipment revenue behaves differently again. Two pharmacies each filling 300 scripts a day can differ by a factor of three in earnings, and the buyer is buying earnings.

• Gross margin per script, split between brand and generic.
• Payer mix across Part D, Medicaid, commercial, and cash.
• Front-end and non-dispensing revenue as a share of gross profit.
• Specialty, compounding, long-term care, and clinical service lines with their own margins.

DIR fees and reimbursement pressure

Direct and indirect remuneration fees, which pharmacy benefit managers historically clawed back months after a prescription was dispensed, were moved to the point of sale under a CMS rule effective in 2024. That change removed the retroactive cash-flow shock but did not remove the economics; it moved them forward into the reported reimbursement. For a seller the practical implication is about comparability: your pre-change and post-change financials do not sit on the same basis, and a buyer recasting three years of results will make that adjustment whether or not you explain it. Explaining it yourself, with the underlying data, is the stronger position.

PBM contracts, PSAOs, and network access

Your ability to fill a covered prescription depends on being in the network, and network participation usually runs through contracts negotiated by a pharmacy services administrative organisation on your behalf. Buyers will want to know which PSAO you belong to, which networks you are in, whether any preferred network status exists, and critically whether those contracts survive a change of ownership. Many do not transfer automatically in an asset purchase, and re-credentialing takes time. Accreditation for specialty or durable medical equipment lines follows the same logic. As with home health, this often decides whether the transaction is structured as an equity purchase or an asset purchase.

Inventory is a separate line, always

Pharmacy transactions almost universally price the business on earnings and then add inventory at cost, counted at or immediately before closing by a third-party service. This protects both sides: the seller is paid for what is actually on the shelf, and the buyer does not pay a multiple on stock. Note that inventory priced this way usually sits outside the working capital peg, so read the letter of intent carefully to confirm you are not being asked to deliver the same value twice. It also creates two areas where sellers lose money quietly. Dead and slow-moving stock counted at full cost is usually challenged, so returning or working it down beforehand is worth real money. And controlled substances require a separate, exact accounting with a DEA Form 222 process for transfer, which is not a formality and cannot be rushed.

Licences, DEA registration, and the board

A pharmacy cannot operate without a state board permit, a DEA registration, an NCPDP number, and NPI enrolments, and how these move depends on the structure. In an asset purchase the buyer generally needs a new state permit and DEA registration for the location, which can take weeks to months and typically requires an inspection. In an equity purchase the entity keeps its registrations, subject to notification requirements. Your pharmacist-in-charge designation must also be handled, since the board records a named individual, and if that is you, the buyer needs a replacement in place at closing. Sellers who map these requirements early avoid the single most common cause of a delayed pharmacy closing.

What raises the multiple

The pharmacies that trade above the band have deliberately reduced their dependence on third-party reimbursement, and the EBITDA multiple follows that mix directly. Compounding, whether sterile or non-sterile, carries better margin and a defensible patient base. Long-term care and assisted-living contracts produce steady, contracted volume. Adherence packaging and clinical services such as immunisation, point-of-care testing, and diabetes education deepen the patient relationship. A real front end, delivery routes with density, and durable medical equipment lines all add gross profit that no benefit manager sets. Buyers pay more for these because they are less likely to be repriced by someone else next year.

Who buys independent pharmacies

Independent operators expanding to two or three locations are the most common buyers and often pay the most for a nearby store because of route and buying overlap. Regional independent groups buy for scale in wholesaler negotiations. Employed pharmacists buying their first store are a large share of the market, usually with SBA financing, and this is where seller financing is most often part of the structure. Long-term care and specialty platforms buy pharmacies with those lines specifically, and the pharmacy acquisition brief shows what those buyers are searching for right now. Chain file buyouts, meaning the sale of the prescription file alone rather than the business, remain a floor option and are typically priced per script; they are worth understanding as a benchmark even if you do not want that outcome. Owners can see the pharmacy buyer demand view or start with a buyer-fit check.

Twelve-month preparation list

• Rebuild reporting so margin per script and gross profit by line are visible monthly.
• Work down dead inventory so the closing count is clean.
• Grow at least one non-PBM revenue line deliberately.
• Confirm PSAO, network, and wholesaler contract treatment on a change of control.
• Identify a pharmacist-in-charge who is not you, and get them on the record.
• Reconcile controlled substance records and perpetual inventory.